Immunocore : Corporate Presentation – June 2024

Transformative immunomodulating medicines for patients

June 2024

1

Forward Looking Statements

This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "believe", "expect", "plan", "anticipate", "estimate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are int ended to identify forward-looking statements. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These statements include, but are not limited to, Immunocore's capabilities across oncology, autoimmune and infectious disease therapeutic areas and its ability to grow and further development the PRAME franchise; the estimated market size and patient population for KIMMTRAK and Immunocore's other product candidates, including the target potential of T cell receptor therapeutics ; the three growth areas of KIMMTRAK including HLA-A02+ melanoma, metastatic cutaneous melanoma and adjuvant uveal melanoma; expected submission of investigational new drug applications or clinical trial applications; the potential regulatory approval, expected clinical benefits and availability of Immunocore's product candidates; the commercial performance of KIMMTRAK including planned launches in additional countries, expanded access to KIMMTRAK in the United States and globally, and indication expansion; the potential benefits and advantages KIMMTRAK and Immunocore's other product candidates will provide for patients; the benefits of Immunocore's collaboration with the European Organisation for Research and Treatment of Cancer ( ); the potential of the PRAME franchise opportunity to expand into additional solid tumor indications; expectations regarding the design, progress, timing, enrollment, scope, expansion, funding, and results of Immunocore's existing and planned clinical trials, those of Immunocore's collaboration partners or the combined clinical trials with Immunocore's collaboration partners; the timing and sufficiency of clinical trial outcomes to support potential approval of any of Immunocore's product candidates or those of, or combined with, its collaboration partners; Immunocore's ability to develop new product candidates using its discovery engine; Immunocore's ability to initiate CMC manufacturing for autoimmune candidates on the expected timeline, or at all; expected commercial and clinical milestones and Immunocore's ability to achieve those milestones on their expected timeline, or at all; and potential growth opportunities and trends, including in connection with product launches. Any forward-looking statements are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond Immunocore's control. These risks and uncertainties include, but are not limited to, the impact of worsening macroeconomic conditions on Immunocore's business, financial position, strategy and anticipated milestones, including Immunocore's ability to conduct ongoing and planned clinical trials; Immunocore's ability to obtain a clinical supply of curr ent or future product candidates or commercial supply of KIMMTRAK or any future approved products, including as a result of health epidemics or pandemics, war in Ukraine, the conflict between Hamas and Israel, the broader risk of a regional conflict in the Middle East, or global geopolitical tension; Immunocore's ability to obtain and maintain regulatory approval of its product candidates, including KIMMTRAK; Immunocore's ability and plans in continuing to establish and expand a commercial infrastructure and to successfully launch, market and sell KIMMTRAK and any future approved products; Immunocore's ability to successfully expand the approved indications for KIMMTRAK or obtain marketing approval for KIMMTRAK in additional geographies in the future; the delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise; Immunocore's ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at

all; competition with respect to market opportunities; unexpected safety or efficacy data observed during preclinical studies or clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical

trials or future regulatory approval; Immunocore's need for and ability to obtain additional funding, on favorable terms or at all, including as a result of worsening macroeconomic conditions, including changes inflation and interest rates and unfavorable general market conditions, and the impacts thereon of the war in Ukraine, the conflict between Hamas and Israel, and global geopolitical tension; Immunocore's ability to obtain, maintain and enforce intellectual property protection for KIMMTRAK or any product candidates it or its collaborators are developing; and the success of Immunocore's current and future collaborations, partnerships or licensing arrangements, including the risk that Immunocore may not realize the anticipated benefits of its collaboration with Bristol Myers Squibb. These and other risks and uncertainties are described in greater detail in the section titled "Risk Factors" in Immunocore's filings with the Securities and Exchange Commission, including Immunocore's most recent Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission on February 28, 2024, as well as discussions of potential risks, uncertainties, and other important factors in Immunocore's subsequent filings with the Securi ties and Exchange Commission.

All forward looking statements contained in this presentation speak only as of the date on which they were made and should not be relied upon as representing its views as of any subsequent date. Except to the extent required by law, Immunocore undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Certain information contained in this presentation relates to or is based on studies, publications, surveys, and other data obtained from third party sources and Immunocore's own internal estimates and research. While Immunocore believes these third party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy, or completeness of, any information obtained from third party sources.

KIMMTRAK™ is a trademark owned or licensed to Immunocore.

2

Harnessing the immune system to fight disease with targeted, off-the-shelf, bispecific, soluble T cell receptors (TCRs)

Targeting

>90% ImmTAX

Proteome

TCR therapeutics can target >90% of the human proteome

3

Platform candidates and capabilities across 3 therapeutic areas

Oncology	Infectious diseases
ImmTACs	ImmTAVs

Autoimmune diseases

ImmTAAIs

Activation

of the immune system

Downmodulation

of the immune system

4

Leading bispecific TCR pipeline

Oncology

Autoimmune Infectious

Candidate	Target (HLA type)	Indication	IND-enabling	Phase 1	Phase 2	Phase 3	Approved
		Uveal (ocular) melanoma						On Market
	gp100 (A02)	Adjuvant uveal (ocular) melanoma	ATOM sponsored by				Phase 3 Start | 2H24
		2L+ advanced cutaneous melanoma	TEBE-AM				Phase 3 ongoing
IMC-F106C	PRAME (A02)	1L advanced cutaneous melanoma	PRISM-MEL-301				Phase 3 Start | 2Q24
		2L+ cutaneous melanoma						Phase 1 Data | ASCO 2024
		PRR ovarian1						Phase 1 Data | 3Q24
		2L+ NSCLC						Phase 1 Data | 4Q24
		Advanced endometrial						Phase 1 Data | 2025
		Multiple solid tumors	Mono. & combination arms
IMC-P115C	PRAME-HLE (A02)	Multiple solid tumors						IND/CTA | Mid-24
IMC-T119C	PRAME (A24)	Multiple solid tumors						IND/CTA | 4Q24
IMC-R117C	PIWIL1 (A02)	Colorectal and GI cancers						Phase 1 Start | 2H 2024
IMC-M113V2	Gag (A02)	Human Immunodeficiency Virus (HIV)						MAD Data | 2H 2024
IMC-I109V	Envelope (A02)	Hepatitis B Virus (HBV)
IMC-S118AI	PPIxPD1 (A02)	Type 1 Diabetes
Undisclosed	(universal)3	Dermatology

5	1 Platinum refractory or resistant serous ovarian carcinoma. 2 Program is wholly owned, development costs being provided by the Bill & Melinda Gates Foundation (BMGF), Immunocore retains all development and
commercialization rights in the developed world. 3 Program is not HLA restricted (i.e. universal for all populations)

Maximizing potential of KIMMTRAK®

in HLA-A02+ melanoma

KIMMTRAK's

3 growth areas

Continued growth in US and global launches (incl. EU)

(FY23 sales ~$239M)

Phase 3 2L+ cutaneous melanoma (TEBE-AM)

(Phase 3 underway)

Phase 3 in adjuvant uveal melanoma (ATOM)

(Phase 3 expected to start 2H 2024)

KIMMTRAK Estimated Market Opportunity

Today

Metastatic	Adjuvant
Uveal Melanoma
Uveal Melanoma
~1,000 pts†	~1,200 pts1

2L+ Advanced

Cutaneous Melanoma

~2,000 - 4,000 pts†

7	1 Estimated number of HLA-A*02:01 positive patients per year in the US and EU.

We continue to reach more patients with KIMMTRAK

$70M	1L
1Q 2024 net sales

Approved in

38

countries

standard of care in launched markets

Launched in

17

countries2

Treated

>1.5K

patients in trials,

EAP1 & commercial

Published

3 yr

OS in NEJM

8	1 Early Access Program (EAP). 2 US, Germany, France, Israel, Italy, Austria, Finland, Belgium, Switzerland, Slovenia, Australia, Canada, Spain, Bulgaria, Luxemborg, Czech Republic, and Lithuania

Overall survival benefit of KIMMTRAK vs investigator's choice in 1L mUM

3-year OS follow-up

27%

KIMMTRAK arm

17%

Investigator's choice arm2

9	Nathan, P. et al. New England Journal of Medicine 2021; 385:1196-1206. Hassel, J., Piperno-Neumann, S. et al. New England Journal of Medicine 2023;
10.1056/NEJMoa2304753.

KIMMTRAK TRAEs mostly in first month and decrease thereafter

Adverse events manageable, very low rate of discontinuation (2%) & no treatment-related deaths

The KIMMTRAK U.S. Prescribing Information has a BOXED WARNING for the risk of Cytokine Release Syndrome. CRS, which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated.

10	* Rash, hypotension, and liver function tests are composite terms for a list of related adverse events of any grade AE: adverse event; TRAE: treatment-related adverse event